MOLECULAR DOCKING AND PHARMACOKINETIC PREDICTION OF HERBAL DERIVATIVES AS MALTASE-GLUCOAMYLASE INHIBITOR by Ochieng, Peter Juma et al.
Vol 10, Issue 9, 2017
Online - 2455-3891 
Print - 0974-2441
MOLECULAR DOCKING AND PHARMACOKINETIC PREDICTION OF HERBAL DERIVATIVES AS 
MALTASE-GLUCOAMYLASE INHIBITOR
PETER JUMA OCHIENG1,3*, TONY SUMARYADA1,2, DANIEL OKUN3
1Department of Physics, Computational Biophysics and Molecular Modeling Research Group, Bogor Agricultural University, Bogor 16680, 
Indonesia. 2Tropical Biopharmaca Research Center, Bogor Agricultural University, (IPB), Jl. Taman Kencana No. 3, Bogor 16680, Indonesia. 
3Department of Biochemistry and Biotechnology, Kenyatta University, P.O.BOX 43844-00100, Nairobi, Kenya. 
Email: peter_ochieng@apps.ipb.ac.id
Received: 21 April 2016, Revised and Accepted: 02 June 2017
ABSTRACT
Objective: To perform molecular docking and pharmacokinetic prediction of momordicoside F2, beta-sitosterol, and cis-N-feruloyltyramine herbal 
derivatives as maltase-glucoamylase (MGAM) inhibitors for the treatment of diabetes.
Methods: The herbal derivatives and standard drug miglitol were docked differently onto MGAM receptor using AutoDock Vina software. In 
addition, Lipinski’s rule, drug-likeness, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties were analyzed using 
Molinspiration, ADMET structure–activity relationship, and prediction of activity spectra for substances online tools.
Results: Docking studies reveal that momordicoside F2, beta-sitosterol, and cis-N-feruloyltyramine derivatives have high binding affinity to the MGAM 
receptor (−7.8, −6.8, and −6.5 Kcal/Mol, respectively) as compared to standard drug miglitol (−5.3 Kcal/Mol). In addition, all the herbal derivatives 
indicate good bioavailability (topological polar surface area <140 Ȧ and Nrot <10) without toxicity or mutagenic effects.
Conclusion: The molecular docking and pharmacokinetic information of herbal derivatives obtained in this study can be utilized to develop novel 
MGAM inhibitors having antidiabetic potential with better pharmacokinetic and pharmacodynamics profile.
Keywords: Absorption; distribution; metabolism; excretion; and toxicity, Herbal derivatives, Maltase-glucoamylase, Molecular docking, 
Pharmacokinetics.
INTRODUCTION
Diabetes syndrome is a metabolic disorder, which causes congenital 
(type I insulin-dependent) or acquired (type II noninsulin-dependent) 
diabetes mellitus, and approximately 7% of the world population is 
suffering from this chronic disorder [1-4]. This chronic disease not only 
affects the carbohydrate metabolism but also alters lipid and protein 
metabolism in advanced stages, leading to complications such as 
microvascular or macrovascular which are more fatal than the primary 
diabetic state; thus, all credit goes to regulating postprandial glucose 
levels [5-7]. One of the therapeutic approaches to regulate blood glucose 
level in an individual with type 2 diabetes is to inhibit R-amylases and 
intestinal glucosidases activity using R-glucosidase inhibitors such as 
acarbose and miglitol [8-10].
Currently, acarbose and miglitol are the only α-glucosidase inhibitors 
which make up a class of antihyperglycemic drugs for regulating 
postprandial glucose levels by reversibly inhibiting digestive α-amylases 
and α-glucosidases [11-14]. Generally, it was believed that carbohydrate 
mimics contain nitrogen; for instance, acarbose and miglitol are 
protonated in the active site and act as glycosidase inhibitors due to 
their ability to mimic the shape or charge of the presumed transition 
state for enzymatic glycoside hydrolysis [15].
N-terminal catalytic domain of maltase-glucoamylase (ntMGAM) is one 
of the intestinal glucosidase targets. In human’s family, GH311 glycoside 
hydrolases MGAM is responsible for the digestion of terminal starch 
products left after R-amylase action into glucose. This membrane-bound 
enzyme contains two catalytic subunits: N-terminal subunit (ntMGAM) 
proximal to the membrane-bound end and C-terminal luminal subunit 
(ctMGAM) [16,17]. Therefore, to inhibit the enzyme’s function, herbal 
drugs have been used to replace the synthetic drugs such as acarbose 
and miglitol which often present adverse effects to some diabetic 
individuals. Studies showed extracts from Momordica charantia, 
Tinospora cordifolia, and Zingiber officinale herbal plants to contain 
alkaloid compounds with α-glucosidase inhibitory properties with 
hypoglycemic effect on several animal studies and small-scale human 
studies [18-21]. Moreover, it has been reported that consumption of 
M. charantia in raw or juice form can be efficacious in lowering blood 
glucose levels [22,23].
The previous study on molecular docking revealed that momordicoside 
F2, beta-sitosterol, and cis-N-feruloyltyramine compounds have higher 
binding affinity to MGAM receptor with the potential to cure type 2 
diabetes. However, the structural function and molecular properties 
for their drug-likeness remain unknown. Related on in silico studies 
have indicated molecular docking to be a robust and reliable approach 
to screen for drug-likeness of molecules [24-26]. In drug discovery, 
structure-based drug design is a vital tool for the discovery and 
development of new molecules using X-ray crystal structure of a protein 
from protein data bank (PDB) [27-30]. In molecular modeling, drug-
receptor complex stability, exact binding mode, and ligand interaction 
with amino acids of the protein molecule can be visualized using 
various docking approaches to discover the pharmacological properties 
of drug molecules [31].
The current study utilizes in silico molecular docking and 
pharmacodynamics prediction to elucidate the drug-likeness, Lipinski’s 
rule, and absorption, distribution, metabolism, excretion, and toxicity 
(ADMET) properties of momordicoside F2, beta-sitosterol, and cis-N-
feruloyltyramine herbal derivatives as MGAM inhibitor.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i9.19337
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MATERIALS AND METHODS
Ligands and protein preparation
The three herbal derivatives were selected based on previous network 
pharmacology study [32]. The 3D ligands structure of beta-sitosterol 
(CID: 222284) from the Z. officinale herb, cis-N-feruloyltyramine (CID: 
5280537, also known as Moupinamide) from Tinospora crispa herb, 
and momordicoside F2 (CID: 44445567) from M. charantia as well as 
the standard drug miglitol (CID: 441314) were all downloaded from 
PubChem online database [33].
The crystal structure of receptor MGAM (PDB code 2QMJ) protein was 
downloaded from RCSB PDB [34] at a resolution of 1.9 Å and refined by 
subtracting water molecules as well as the addition of hydrogen bond 
and Gasteiger-Huckel charges. All the data files for ligands and receptor 
were then saved in PDBQT format.
Docking protocol
The AutoDock Vina [35] program installed in 4 GHz Intel Core i3 
processor and 4GB RAM, having Windows 8 Professional as an 
operating system, was utilized to perform automated docking studies 
to predict the protein–ligand interaction. The active site for MGAM 
(2QMJ) was selected and the grid size was set as x = −27.643, y = 
−12.49, and z = −0.559 with the box size set to z = 30, y = 30, and 
x = 36. In addition, the number of exhaustiveness was set at 20 to 
compromise the global search and local minimum for optimal 
docking results. To validate the docking protocol for the three herbal 
derivatives, miglitol was used as the standard ligand. In the proposed 
docking protocol, ligands were kept flexible while amino acid in 
protein was held rigid after which each ligand was docked onto 
the active site of the MGAM receptor [36-38]. The scoring function 
(Gibbs-free energy/binding affinity) for the ligand–MGAM complex 
was computed using AutoDock Vina program, while interaction 
between MGAM amino acids residues and herbal derivatives with 
respect to H-bond and hydrophobic bonds on the binding sites was 
analyzed using LigPlot+ v.1.4 program [39].
The AutoDock Vina program uses free energy empirical scoring 
functions where binding energy decomposes into several energy 
components including hydrogen bond, ionic interaction, hydrophobic 
effect, and binding entropy. AutoDock scoring function is calculated by 
the equation below.
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Where ΔG is the estimated free binding energy; ΔG0 is the regression 
constant; ΔGrot, ΔGhb, ΔGio, ΔGaro, and ΔGlipo are regression coefficients 
for each corresponding free energy term; f (ΔR, Δα) is scaling function 
for penalizing ideal geometry deviations; Nrot is the number of free 
rotatable bonds that are immobilized in the complex [40].
Prediction of molecular properties
Lipinski’s rule of five (RO5) was used to evaluate drug-likeness to 
determine if the herbal derivatives have certain pharmacological or 
biological activity that would make them an orally active drug-like 
moiety for humans [41,42].
Thus, essential molecular properties such as molecular weight, 
hydrogen bond donor, hydrogen bond acceptor, number of the rotatable 
bonds, and logP for each herbal derivatives (momordicoside F2, cis-N-
feruloyltyramine, and beta-sitosterol) were calculated using MedChem 
Designer (www.simulations-plus.com).
Prediction of bioactivity score
Bioactivity of momordicoside F2, cis-N-feruloyltyramine, and beta-
sitosterol herbal derivatives can be checked by calculating the activity 
score of G-protein-coupled receptor (GPCR) ligand, ion channel 
modulator, nuclear receptor ligand, kinase inhibitor, protease inhibitor, 
and enzyme inhibitor [43]. All these parameters were calculated using 
Molinspiration drug-likeness (www.molinspiration.com), an online 
server database. Here, calculated drug-likeness scores for each herbal 
derivative were then compared with that of standard drug miglitol.
Prediction of ADMET properties for the herbal derivatives
Drugs are often withdrawn at the different phases of the clinical trials 
due to poor ADMET properties and adverse effects probably associated 
with their molecular structures. Therefore, it is important to predict 
ADMET properties during the lead identification and optimizations. 
Here, we used ADMET SAR a free online server to predict ADMET 
properties such as blood–brain barrier (BBB)+ penetration, human 
intestinal absorption (HIA), biodegradability, CaCO2 permeability, 
AMES toxicity, carcinogenicity, rat acute toxicity. Thus, we estimated the 
ADMET properties of the compounds using admetSAR online database 
(www.lmmd.ecust.edu.cn) which comprises data for different entities 
linked with known ADMET profiles [44].
Therapeutic target validation
Structural feature of a molecule in drug design plays an essential role in 
correcting therapeutic targets or therapeutic disease. Here, prediction 
of activity spectra for substances (PASS), an online software tool that 
predicts more than 300 pharmacological effects and biochemical 
mechanisms of compounds based on their structural information [45], 
was used to screen the possible therapeutic targets for the herbal 
derivatives. PASS (Prediction of activity spectra for substances) software, 
predicted the probability of activity (Pa) and inactivity (Pi) values for 
each herbal derivatives to identify the possible inhibitory targets.
RESULTS AND DISCUSSION
In the current study, the binding affinity and binding site similarity 
(BSS) score for herbal derivatives and standard drug miglitol onto 
MGAM receptor were evaluated by molecular docking approach using 
AutoDock Vina software. The molecular properties and biological 
activity of the herbal derivatives were further analyzed by online tools 
to predict their pharmacokinetics and pharmacodynamics profiles as 
future candidate compounds to develop the antidiabetic drug.
The chemical structure and function of momordicoside F2, 
cis-N-Feruloyltyramine and beta-sitosterol herbal derivatives (Fig. 1) were 
utilized to predict scoring functions and their biological interaction with 
amino acid residues of MGAM receptor previously obtained from Protein 
Data Bank. From the docking analysis binding pattern of herbal derivatives 
were found to vary with the molecular conformation of the ligand [46-48].
The previous pharmacophore study showed momordicoside F1 and 
miglitol to have similar BSS score (100%) to MGAM receptor. However, 
H-bond interactions for both compounds with MGAM were different. 
Miglitol compound was involved in H-bond interaction with four amino 
acid residues (Asp702, Leu727, Ile 725 and Glu719) of MGAM with 
binding affinity of -5.3 Kcal/Mol whereas, momordicoside F1 interacted 
with Gln 708, Glu704, Try 626 and Ile725 amino acid residue with -7.8 
Kcal/Mol binding affinity. In addition, the momordicoside F2 compound 
was also involved in H-bond interaction with seven amino acids of 
MGAM protein (Lys724, Asp702, leu720, Glu719, leu727, Glu704, and 
Ile725). On the other hand, cis-N-feruloyltyramine compounds showed 
a binding pattern with 12 different amino acids residues with six amino 
acid residues involved in H-bond and hydrophobic interaction at target 
binding site where four amino acid residues (Glu719, Leu720, Asp702, 
and Lys 724) were involved in the H-bond interaction while two amino 
acid residues (Ile 725 and Glu704) involved in hydrophobic interaction 
with BSS score (85.71%) and binding affinity (−6.50 Kcal/Mol).
Beta-sitosterol demonstrated high BSS score (85.71%) and binding 
affinity (−6.8 Kcal/Mol) with MGAM receptor. This explains that its 
antidiabetic potential is due to hydrophobic interactions with MGAM 
amino acids residues (Ile725, Glu704, Lys724, Glu719, Asp702, and 
Leu720) with the absence of H-bond interaction. The molecular 
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docking revealed that the hydrophobic pocket of MGAM comprises nine 
interaction amino acid residues where four residues (Asp702, Leu727, 
Ile 725, and Glu719) are responsible for hydrogen bond formation 
during the interaction while five residues (Hsd728, Gly726, Leu720, 
Glu704, and Lys 724) form a hydrophobic pocket responsible for direct 
or indirect hydrophobic interaction. Previous studies have reported 
that the linker between the polar head and hydrophobic tail plays an 
important role in binding the ligand with MGAM [49-51]. The previous 
pharmacophore study revealed three herbal derivatives and standard 
drug miglitol to have common binding sites (Ile725, Glu704, Lys724, 
Leu720, Asp702, and Glu719) at MGAM binding pockets. Thus, the 
binding property of the herbal derivatives onto MGAM indicates their 
potential to inhibit MGAM activity.
To further understand the molecular properties of the herbal 
derivatives, we utilize Molinspiration an online tool to analyze the 
molecular lipophilicity potential (MLP). MLP is a useful property to 
rationalize various molecular ADME properties such as membrane 
penetration or plasma protein binding. Thus, it is important to identify 
which parts of their molecular surface of a compound are hydrophobic 
(encoded by violet and blue colors) and/or hydrophilic (encoded 
by orange and red). MLP analysis (Fig. 2) reveals momordicoside 
F2, beta-sitosterol, and cis-N-feruloyltyramine to have significant 
hydrophobicity distribution (83.33%, 100%, and 66.57%, respectively) 
whereas miglitol showed hydrophilic distribution (57.14%). 
Hydrophobicity distribution on the molecular surface of the drug 
molecules plays an important role when distinguishing the observed 
ADME properties of drug molecules with respect to their lipophilicity 
(logP) values [52-54]. The three investigated herbal derivatives show 
better MLP hydrophobicity distribution as compared to miglitol drug. 
Therefore, we utilized the calculated MLP from atomic hydrophobicity 
to compute the logP (Table 1).
The molecular descriptors of herbal derivatives and standard drug 
miglitol were evaluated for Lipinski’s RO5. From the analysis, cis-N-
feruloyltyramine, beta-sitosterol, and miglitol compounds have molecular 
weight within the range of 200-500 g/Mol, except for momordicoside 
F2 (618.852 g/Mol) which exceeds the Lipinski’s limit. Molecular weight 
plays an important role with respect to drug action because as the 
molecular weight increases beyond the certain limit, the surface area 
of the compound also increases correspondingly; consequently, this 
affects the penetrability of the drug compound [55,56]. Likewise, cis-
N-feruloyltyramine, beta-sitosterol, and miglitol had similar range for 
molecular volume, except momordicoside F2 which exceeded the range 
(603.90). Molecular volume of drug molecule determines its transport 
characteristics such as intestinal absorption or BBB penetration; hence, 
it is an important parameter when evaluating molecular properties and 
biological activity of the investigated herbal derivatives.
Fig. 1: Chemical structures of momordicoside F2, cis-N-feruloyltyramine, beta-sitosterol, and standard drug miglitol
Fig. 2: Surface representation of molecular lipophilicity potential 
for (a) momordicoside F2, (b): Cis-N-feruloyltyramine, (c) beta-
sitosterol, and (d) standard drug miglitol. The hydrophobic 
surface are encoded by violet and blue colors and hydrophilic 
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Prediction of transport properties for herbal derivatives was critical 
to determine their correlation with the HIA, CaCO2 monolayers 
permeability, and BBB penetration. As mentioned previously in the 
analysis of MLP, lipophilicity (logP) and topological polar surface 
area (TPSA) play two major factors which influence the permeability 
of the compounds as well as determine oral bioavailability [57]. The 
TPSA was obtained by calculating the total surface areas occupied 
by oxygen and nitrogen atoms as well as hydrogen attached to these 
molecules. This revealed the relationship of the potential of hydrogen 
bonding with the TPSA value of those compounds. The lipophilicity 
for the herbal compound and standard drug miglitol was analyzed by 
Molinspiration online tool and was found to be logP <10. In addition, it 
has been reported that compounds having TPSA≤140 Ȧ and rotational 
bonds Nrot≤10 are more likely to have good bioavailability due to 
rotational bonds that make the compounds flexible, hence easily 
interact with specific rigid binding area [58]. The results indicated 
that all herbal derivatives and standard drug miglitol demonstrated 
good numbers of rotational bonds and TPSA value within limits 
(Table 1).
Drug solubility alongside permeability plays a vital role since 
those parameters often influence the pharmacokinetic and 
pharmacodynamics properties of drugs starting from the site of 
administration, absorption into systemic circulation, and movement 
in the blood and excretion. Therefore, ADMET of the compounds was 
calculated using online dataset admetSAR mention previously in the 
materials and methods section. In this analysis, different permeability 
such as BBB penetration, HIA, CaCO2 cell permeability, renal organic 
cation transport, and AMES toxicity were tested. A study has shown 
that cytochrome P450 (CYP) enzymes are mainly involved in the drug 
metabolism for elimination and biotransformation. Furthermore, it 
has been reported that drug–drug interactions can activate or inhibit 
CYP enzymes; thus, coadministration of the drug may accumulate to 
toxic level due to inhibition of CYP enzymes or rapid excretion due to 
activation of CYP microsomal enzymes [59]. In clinical pharmacology, 
P-glycoproteins are the main reason for drug resistance (low cell 
susceptible to drugs). These proteins are often involved in the efflux 
and their activation would lead to increase in drug efflux, hence 
lowering drug concentration below the minimum required level which 
may result in therapeutic failure [60].
The three investigated herbal derivatives did not show interaction with 
P-glycoprotein (Table 2). Apart from P-glycoproteins, tumorigenic or 
carcinogenic may also have a direct or indirect correlation with the 
molecular properties of those compounds. Thus, carcinogenicity, oral 
toxicity, and acute dose toxicity in the rat (LD50) of the three compounds 
were also tested and the results summarized in supplementary file S2. 
Based on the admetSAR results, all the herbal derivatives can permit 
through the intestine barrier and absorbed from the human intestine 
without any toxicity or mutagenicity.
Most drugs often act by interacting with different GPCR ligands, nuclear 
receptors, or different kind of enzymes, ion channels, protease, viz., 
kinase. Interaction of chemical compounds with these biomolecules 
tends to indicate their drug-likeness.
Thus, all the herbal derivatives were screened for their drug-likeness 
using Molinspiration online tool previously mentioned in the 
Materials and Methods section (comprehensive results are provided 
in supplementary file S1). In the analysis, it was hypothesized that 
molecules having a positive biological value (more than 0.00) are 
supposed to have good biological activity and those having biological 
score <−0.50 are considered to be biologically inactive while 
compounds with value in between −0.50 and 0.00 are recognized as a 
mild to moderate active [61]. All the compounds were docked different 
onto MGAM receptor (a brush border membrane enzyme responsible 
for digestion dietary starch to glucose) with assumption that the herbal 
derivatives possess good MGAM inhibitory activity. The predicted 
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active with a good biological score <0.00, thus capable of having 
pharmacological action through interaction with the enzyme receptor.
Although miglitol compound indicated the poor biological score for 
nuclear receptors (−0.82), study has reported miglitol drug to have 
significant biological activity with MGAM in streptozotocin-induced 
diabetic rats [62]. Both momordicoside F2 and beta-sitosterol herbal 
derivatives showed a good biological score for kinase inhibition, which 
may modulate disease state by an alteration in the signal cascading 
pathway. Furthermore, we performed in silico validation using PASS 
online software to check the common therapeutic activities for the 
three investigated herbal derivatives and summarized results in 
supplementary file S3. The results revealed the herbal derivatives 
were mainly involved in R-glucosidase, mannosidase, and GPCR 
kinase 2 (GRK2) inhibitory activities (Table 4). This indicates that 
momordicoside F2, cis-N-feruloyltyramine, and beta-sitosterol herbal 
derivative may act as R-glucosidase inhibitor by competitively and 
reversibly inhibiting alpha-glucosidase in the intestines. Thus, this 
inhibition lowers the rate of glucose absorption through delayed 
carbohydrate digestion and extended digestion time [63,64]. Hence, 
the three herbal derivatives may have the probably cure diabetic 
disease by inhibiting MGAM activity. In addition, momordicoside F2, 
cis-N-feruloyltyramine, and beta-sitosterol herbal derivatives act as 
a GRK2 inhibitor. GRK2 can act as an inhibitor of insulin-mediated 
glucose transport stimulation in 3T3L1 adipocytes by interacting with 
Gαq/11 function independently of its kinase activity [65]. GRK2 also 
inhibits basal and insulin-stimulated glycogen synthesis in mouse liver 
FL83B cells [66]. In that context, PASS validation results revealed that 
the investigated herbal derivatives have higher probability of inhibiting 
GRK2 activity and this may play a relevant physiological role in the 
modulation of insulin responses [67,68]. Studies have shown GRK2 
expression is increased in key tissues in different experimental models 
of insulin resistance, and a 50% downregulation of GRK2 levels in 
hemizygous GRK2+/− mice is sufficient to protect against TNF-α, aging, 
or high-fat diet-induced alterations in glucose homeostasis and insulin 
signaling, strongly arguing for a key role for GRK2 in the modulation of 
insulin sensitivity in physiological and pathological conditions [69,70]. 
From this analysis, momordicoside F2, cis-N-feruloyltyramine, and 
beta-sitosterol herbal derivatives show a significant therapeutic 
activity with glucosidases and GRK2; thus, the herbal derivatives may 
be promising lead compounds for the development of other MGAM 
inhibitors.
CONCLUSION
Discovery of new alpha-glucosidase (MGAM) inhibitors with potential 
biological activity and minimal or no adverse effect is an exigent need 
for efficient treatment of diabetes. The current study successfully 
utilizes molecular docking and pharmacokinetic predictions of 
momordicoside F2, cis-N-feruloyltyramine, and beta-sitosterol herbal 
derivatives as MGAM inhibitor in the treatment of diabetes disease. 
Docking results revealed the three investigated herbal derivatives 
significantly interaction with MGAM amino acid residues in respect 





















Miglitol −0.41 −0.10 −0.53 −0.82 0.11 0.36 0.7325 0.927 0.9022
cis-N-Feruloyltyramine 0.10 −0.06 −0.16 0.05 −0.05 0.02 0.7851 0.7056 0.6571
Momordicoside F2 0.26 −0.39 0.48 0.23 0.20 0.30 0.6589 0.8953 0.8537
Beta-sitosterol 0.14 0.04 0.51 0.73 0.07 0.51 0.681 0.9291 0.9125
Non inhibitor Non inhibitor Non inhibitor
GPCR: G-protein-coupled receptor, CYP: Cytochrome P450
Table 4: Common therapeutic activities for momordicoside F2, cis-N-feruloyltyramine, and beta-sitosterol herbal derivatives
Therapeutic activity Probability of activity (Pa) Probability of inactivity (Pi)
Mannosidase inhibitor 0.963 0.000
Alpha-mannosidase inhibitor 0.960 0.000
Mannosyl-oligosaccharide 1,2-alpha-mannosidase inhibitor 0.897 0.001
Oligo-1,6-glucosidase inhibitor 0.893 0.001
Sucrose alpha-glucosidase inhibitor 0.880 0.000
Alpha-glucosidase inhibitor 0.879* 0.001
Glucan 1,4-beta-glucosidase inhibitor 0.517 0.006
G-protein-coupled receptor kinase 2 inhibitor 0.550* 0.025
Glucose-6-phosphate translocase inhibitor 0.542* 0.006
*Significant inhibitory activities





















Miglitol 0.5422 0.7375 0.6354 0.6749 0.9931 0.9535 0.9968 0.5797
cis-N-Feruloyltyramine 0.9884 0.5778 0.6064 0.7233 0.6972 0.7674 0.6502† 0.9668
Momordicoside F2 0.6325 0.8532 0.6589 0.7706 0.9600 0.9453 0.9105† 0.9556
Beta-sitosterol 1.0000 0.7953 0.6877 0.8098 0.8309 0.9346 0.5244† 0.8027





ADMET: Absorption, distribution, metabolism, excretion, and toxicity, CYP: Cytochrome P450, HIA: Human intestinal absorption, †Significant value
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to H-bonding and hydrophobic interaction. The similarity score and 
binding affinity support the hypothesis that three herbal derivatives 
from Z. officinale, T. crispa, and M. charantia medicinal plants may 
have substantial antidiabetic property by inhibiting MGAM activity. 
Moreover, pharmacodynamics prediction of a biological score and 
ADEMT activity indicates the three herbal derivatives could be 
promising lead molecules for the development of the novel antidiabetic 
agents, and in the future analogs, compounds hold immense potential 
to develop a competent therapy for diabetes. However, further in vivo 
and in-vitro studies will help decipher potential biological activity of the 
three herbal derivatives with MGAM as an alpha-glucosidase inhibitor 
with significant antidiabetic effects.
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